Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma (NCT04792073)
A Phase II Single-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy With Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)
🩺 Plain-English Summary (8th-Grade Level)
This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
- Memorial Sloan Kettering Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Merkel Cell Carcinoma
- Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma — Tampa, Florida
- Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies — Phoenix, Arizona
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma — Tampa, Florida
- Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns — San Francisco, California
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 — Madison, Wisconsin
Explore by condition: All Merkel Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.